Guardant Complete

Testing Across the
Continuum of Cancer

A comprehensive portfolio of liquid and tissue precision oncology tests for patients diagnosed with early or advanced-stage cancer.

Guardant 380

Expanded Liquid Testing With Genomic and Epigenomic Insights

Guardant360 Liquid is the first and only liquid biopsy to deliver genomic and epigenomic insights for a more complete view of cancer.18 By analyzing cell-free DNA, Guardant360 Liquid helps healthcare providers detect actionable genomic and epigenomic alterations to guide personalized treatment and monitor tumor evolution. Guardant360 Liquid is guideline-recommended across all advanced solid tumors and has broad commercial and Medicare coverage for advanced solid tumors.

Learn More

Guardant 360 CDx

A Fast CGP Panel With Guideline-Recommended Actionable Biomarkers

Guardant360 CDx is our FDA-approved liquid biopsy that provides results in less than 7 days to inform treatment decisions.1 Guardant360 CDx has broad commercial and Medicare coverage for all advanced solid tumors.2

Learn More
Guardant 360 TissueNext

Guardant360 Tissue logo

Unlock Maximum Insights From Minimal Tissue With Advanced Multiomics

Guardant360 Tissue is a multiomic test for patients with advanced solid tumors, providing comprehensive genomic, transcriptomic, and epigenomic insights19 using minimal tissue—requiring 92% less surface area20 and 40% fewer slides than the industry standard.21 Guardant360 Tissue has broad commercial and Medicare coverage for advanced solid tumors.15

Learn More
Guardant Reveal Box
Guardant Reveal

Minimal Residual Disease Detection and Recurrence Monitoring

Guardant Reveal is a completely tissue-free test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients.16

Learn More

Guardant 360 Response

The Only Tissue-Free Biopsy to Measure Treatment Response

Our Guardant360 Response test is the first tissue-free biopsy that enables doctors to view molecular response, or changes in ctDNA levels, to get an early indication of patient response to immunotherapy or targeted therapy for advanced stage solid tumors.17 Studies show the Guardant360 Response test can predict treatment response 8 weeks earlier than current standard-of-care imaging.4-13

Learn More

Best-In-Class
Customer Service Offerings

Medical Affairs Support

On-demand medical experts to answer questions and guide clinical use of Guardant tests

Mobile Phlebotomy Services

An easy and convenience sample collection service that meets patients at their location

Guardant Access Program

Helps patients by minimizing surprise bills and checking eligibility for financial assistance

Digital Ordering with Guardant Portal and EMR Integrations

Simple paperless experience to speed up the ordering process

  1. Fastest median turnaround time for an FDA approved CGP test from sample receipt to results based on real world turnaround times from Integra Connect data.
  2. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 CDx is $5,000 effective the first day of commercial launch September 28, 2020.
  3. Guardant360(™) TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
  4. Data on file. Guardant Health, Inc. Redwood City, CA.
  5. Raja R, Kuziora M, Philip Z. Brohawn PZ, et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res; 2018: 24(24): 6212-6222. DOI: 10.1158/1078-0432.CCR-18-0386.
  6. Aggarwal C,Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.
  7. Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med; 2018: 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z.
  8. Shaw AT, Martini JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol; 2019: 37:15_suppl, 9019-9019. DOI: 10.1200/JCO.2019.37.15.
  9. Pascual J, Cutts RJ, Kingston B, et al. Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-02.DOI: 10.1158/1538-7445.SABCS20-PS5-02.
  10. Mack PC, Redman MW, Moon J, et al. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.J Clin Oncol; 2020: 38:15_suppl, 9532-9532. DOI: 10.1200/JCO.2020.38.15.
  11. Maron SB, Chatila WK, Millang BM, et al, Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. J Clin Oncol; 2020: 38:15_suppl, 4559-4559. DOI: 10.1200/JCO.2020.38.15.
  12. Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol; 2020: 38(17):1887-1896. DOI: 10.1200/JCO.19.02318.
  13. Zhang Q, Luo J, Wu S, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov; 2020: 10:12, 1842-1853. DOI: 10.1158/2159-8290.CD-20-0047.
  14. Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis; 2021: 5, 510-524. DOI: 10.1200/PO.20.0032.
  15. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 Tissue is $5,000 effective the first day of commercial launch April 28, 2025.
  16. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant Reveal is $3,500 effective the first day of commercial launch February 26, 2021.
  17. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 Response is $5,000 effective the first day of commercial launch June 22, 2021.
  18. The first and only commercially available liquid biopsy to deliver genomic and epigenomic insights from a single input.
  19. Guardant360 Tissue Assay Specifications 2025. Guardant Health, Inc. Redwood City, CA.
  20. 2mm2 for Guardant360 Tissue vs 25mm2 industry standard.
  21. 6 slides for Guardant360 Tissue vs 10-slide industry standard for NGS testing only.